Company profile: ExpreS2ion Biotechnologies
1.1 - Company Overview
Company description
- Provider of innovative vaccines and the human clinical Phase III-validated ExpreS2™ technology platform for fast and efficient development of novel, life-saving vaccines that improve quality of life worldwide.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ExpreS2ion Biotechnologies
Biotheranostics
HQ: United States
Website
- Description: Provider of commercial-stage molecular diagnostics, delivering diagnostic, prognostic, and predictive tests that support physicians in treating cancer, including Breast Cancer Index, a genomic test predicting benefit of extended endocrine therapy in HR+, early-stage breast cancer, and CancerTYPE ID, a gene expression assay identifying tumor type/subtype in metastatic cancer with unknown or unclear diagnoses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biotheranostics company profile →
Sequenta
HQ: United States
Website
- Description: Provider of clinical diagnostics and immune profiling tools based on a platform for understanding immune system status. Products include clonoSEQ for MRD detection and monitoring in multiple myeloma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; immunoSEQ for sequencing T- and B-cell receptors; T-Detect to identify recent or past infections, including COVID-19; and an Immune Medicine Platform mapping immune receptors to antigens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sequenta company profile →
OXGENE
HQ: United Kingdom
Website
- Description: Provider of versatile cloning plasmids for research, custom cloning and DNA synthesis, and IP-free products. Offers TESSA technology for scalable, cost-effective AAV manufacturing, high-titre transient rAAV production, cell and gene therapy acceleration services (including CAR-T), cell line development and engineering, and LentiVEX plasmids and cell lines for lentiviral vector production.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OXGENE company profile →
Amyris
HQ: United States
Website
- Description: Provider of biotech chemical products made via advanced sugarcane-derived fermentation. Portfolio includes Neossance Squalane for cosmetics and skincare moisturization and barrier repair; Artemisinic Acid used in antimalarial treatments; Biosilica from sugarcane ashes for cosmetics; Neossance Hemisqualane as a plant-based silicone alternative; Biofene renewable specialty chemical building block; RealSweet Reb M zero-calorie sweetener.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amyris company profile →
Spindiag
HQ: Germany
Website
- Description: Provider of an easy-to-use, compact, automated point-of-care PCR system for broad, fast, and affordable pathogen detection. The Rhonda player with Rhonda disks detects infectious agents—including SARS-CoV-2, Influenza A/B, RSV, and MRSA—with results in under one hour; the SARS-CoV-2 disk supports direct swab insertion. The Rhonda app displays results for mobile use, and test outcomes can be transferred directly into patient records.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spindiag company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ExpreS2ion Biotechnologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ExpreS2ion Biotechnologies
2.2 - Growth funds investing in similar companies to ExpreS2ion Biotechnologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ExpreS2ion Biotechnologies
4.2 - Public trading comparable groups for ExpreS2ion Biotechnologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →